Catalog No.
MHB87401
Species reactivity
Human
Host species
Mouse
Isotype
IgG
Clonality
Monoclonal
Immunogen
Human PIVKA-II/DCP Protein.
Target
Prothrombin, 3.4.21.5, Coagulation factor II, Activation peptide fragment 1, Activation peptide fragment 2, Thrombin light chain, Thrombin heavy chain, F2
Concentration
2.24 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Applications
ELISA
Form
Liquid
Storage buffer
0.02M PBS, pH 7.4, containing 0.1% Preservatives
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
1A301
Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma., PMID:39962429
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy., PMID:39321197
Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma., PMID:39195298
Construction of an immunosensor based on Cys/Au@TiO2 modification for the detection of liver cancer marker PIVKA-II., PMID:38677167
Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases., PMID:38173715
Characterization of Gla proteoforms and non-Gla peptides of gamma carboxylated proteins: Application to quantification of prothrombin proteoforms in human plasma., PMID:37996163
The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma., PMID:37932802
Case report: Unusual development of hepatocellular carcinoma during immunosuppressive treatments against rheumatoid arthritis overlapping Sjögren's syndrome; cirrhotic steatohepatitis with liver inflammation and fibrosis lurks in autoimmune disorders., PMID:36875090
Pathologic Complete Response after Chemotherapy with Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma with Tumor Thrombus in the Main Portal Trunk., PMID:36848877
Whole blood viscosity is associated with extrahepatic metastases and survival in patients with hepatocellular carcinoma., PMID:34855786
Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma., PMID:34731863
Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry., PMID:34558815
A case of resected hepatocellular carcinoma with gallbladder metastasis., PMID:34138407
Prognostic factors of nivolumab in advanced hepatocellular carcinoma: a systematic review and meta-analysis., PMID:33860654
Diagnostic Value of Serum Biomarkers for Patients Undergoing Curative Resection with Non-B, Non-C Hepatocellular Carcinoma., PMID:32036818
A Novel LC-MS/MS Assay for Quantification of Des-carboxy Prothrombin and Characterization of Warfarin-Induced Changes., PMID:32004415
Unique Biological Activity and Potential Role of Monomeric Laminin-γ2 as a Novel Biomarker for Hepatocellular Carcinoma: A Review., PMID:30626121
Development of up-converting phosphor technology-based lateral flow assay for quantitative detection of serum PIVKA-II: Inception of a near-patient PIVKA-II detection tool., PMID:30445030
Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma., PMID:29848691
Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC., PMID:29702392
Myeloma-Derived Light Chain Paired with a Diagnostic Monoclonal Antibody Hinders Immunoassay Performance., PMID:28557609
[Production of an Anti-PIVKA-II Recombinant Single-Chain-Antibody in Escherichia Coli]., PMID:30609478
The serum level of NX-DCP-R, but not DCP, is not increased in alcoholic liver disease without hepatocellular carcinoma., PMID:26600398
Immunomagnetic Reduction Assay on Des-Gamma-Carboxy Prothrombin for Screening of Hepatocellular Carcinoma., PMID:26415145
Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II., PMID:26297114
Serum DHCR24 Auto-antibody as a new Biomarker for Progression of Hepatitis C., PMID:26288822
Des-γ-carboxyprothrombin (DCP) and NX-DCP expressions and their relationship with clinicopathological features in hepatocellular carcinoma., PMID:25739032
Prevalence and correlates of vitamin K deficiency in children with inflammatory bowel disease., PMID:24759680
NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II., PMID:23749928
[History of tumor markers for cancers of the digestive system]., PMID:23692875
Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma., PMID:23480217
Clinical implication of hypovascular hepatocellular carcinoma studied in 4,474 patients with solitary tumour equal or less than 3 cm., PMID:23445409
Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma., PMID:23432345
Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma., PMID:23215762
Multiple ectopic hepatocellular carcinomas arising in the abdominal cavity., PMID:23139654
The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma., PMID:22957256
Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma., PMID:22554520
Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma., PMID:22193346
Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors., PMID:22158026
Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis., PMID:22118699
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome., PMID:21371740
A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma., PMID:21231906
Hepatocellular carcinoma arising from ectopic liver tissue in the spleen producing insulin-like growth factor II., PMID:20943327
Hepatocellular carcinoma associated with noncirrhotic autoimmune hepatitis., PMID:26190005
[Fully automated immunoassay system utilizing microchip electrophoresis]., PMID:20030172
Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma., PMID:19787254
[Evaluation of serum PIVKA-II by Lumipulse PrestoII assay]., PMID:19363989
The role of des-gamma-carboxyprothrombin expression in hepatocellular carcinoma., PMID:18795695
Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma., PMID:18625005
For research use only. Not for human or drug use.
